Madrigal Pharmaceuticals, Inc.
MDGL
Positions held
Your positionsMDGL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Madrigal Pharmaceuticals operates in the biotechnology sector, which is characterized by rapid innovation and significant growth potential, particularly in the treatment of liver diseases.
- The company's revenue increased by 17% in the latest quarter, reaching $364 million compared to $311 million in the previous quarter.
- Madrigal's gross margin remains strong at 89%, indicating efficient production and pricing strategies.
- Madrigal Pharmaceuticals faces intense competition in the biotechnology industry, which can impact market share and pricing power.
- The company reported a net income loss of $57.939 million in the latest quarter, continuing a trend of negative profitability.
- Madrigal's operating margin remains negative at -15.5%, reflecting ongoing challenges in managing operational costs.
Fundamentals
| Market cap | $11.02B | Enterprise value | $10.53B | Trailing P/E | — | Forward P/E | 49.55 |
| PEG | — | Price / book | 21.03 | Beta | -1.05 | Dividend yield | 0.00% |
| Revenue growth | 71.2% | Earnings growth | — | Gross margin | 91.5% | Operating margin | -15.5% |
| Profit margin | -25.3% | ROE | -53.3% | ROA | -17.8% | Debt / equity | 0.66 |
| Current ratio | 3.21 | Free cash flow | -$80.47M | Analyst recommendation | strong_buy | Mean target | $682.11 |
| 52w high | $615.00 | 52w low | $393.61 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $364M | $311M | $321M | $287M | $213M |
| Op margin | -15.5% | -29.8% | -18.6% | -39.7% | -22.2% |
| Net income | -$57.9M | -$94.4M | -$58.6M | -$114M | -$42.3M |
| Gross margin | 89.0% | 91.4% | 92.4% | 93.7% | 95.7% |
| Gross profit | $324M | $284M | $297M | $269M | $204M |
| Operating income | -$56.3M | -$92.7M | -$59.6M | -$114M | -$47.2M |
- Revenue +17% vs prior quarter ($364M vs $311M).
- Gross margin 89% (was 91.4% prior quarter).
- Operating margin expanded to -15.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $958M | $180M | $0.0M | $0.0M | — |
| Op margin | -31.3% | -276.4% | — | — | — |
| Net income | -$288M | -$466M | -$374M | -$295M | — |
| Gross margin | 94.1% | 96.5% | — | — | — |
| Gross profit | $902M | $174M | $0.0M | $0.0M | — |
| Operating income | -$300M | -$498M | -$380M | -$294M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus
2026-10-08 · Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run
2026-10-07 · Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?
2026-10-07 · Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
2026-09-23 · Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
2026-09-16 · Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-09-10 · Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
2026-09-02 · Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
2026-08-25 · Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
2026-08-20 · Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 · Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Price (daily)
Full chart · RSI · MACD · patterns